BmDR
BIOMARKER DATA REPOSITORY
CRITICAL PATH INSTITUTE

Advancing Drug Development. Improving Lives. Together.

December 2024

Dear BmDR Enthusiasts,

Thank you for your continued interest, participation, and contributions to the Biomarker Data Repository (BmDR). The BmDR committees have been busy preparing communications about BmDR updates and connecting with research and patient groups involved in kidney disease. As the final newsletter this calendar year, we have updates on progress towards BmDR's goals and detail the BmDR team's presence at the American Society of Nephrology (ASN) Kidney Week, 2024. We also share valuable excerpts from kidney disease patients, and a blog written by patient representative Glenda Roberts from her perspective on the importance of identifying new biomarkers.

We hope you all enjoy your Holidays and have a happy New Year!

Sincerely,

Nicholas King
Executive Director
Predictive Safety Testing Consortium

Katrina Peron
Associate Director
Predictive Safety Testing Consortium (PSTC)

Latest Developments

Qualified researchers can request access to the BmDR data and analytics platform (DAP) to review and interrogate data, as well as request specific datasets, using this link. Details on accessing the DAP and how to request an account can be found here. Further instructions and details on how to request datasets and analyze them will be reviewed in the next newsletter. The BmDR team is in talks with organizations for an additional seven clinical datasets, which will aid in our goal of expanding the volume and capabilities of the repository. Outreach continues to consortia, academic researchers, and companies with relevant data sets to contribute. Gary Friedman, Nicholas King, and Katrina Peron attended ASN Kidney Week 2024, where they participated in the KPMP Industry Roundtable, PKDOC Annual Symposium Dinner, and presented two posters, detailed below. They continued to spread the word about BmDR and elicit data contributions at the conference, as well.

Contributing to BmDR

Please consider contributing your data to BmDR. Populations of interest to the team include pediatric study populations. If interested or you would like to discuss further details, please contact bmdr@c-path.org, or Nicholas King (nking@c-path.org).

Updates from American Society of Nephrology (ASN) Kidney Week 2024 and KPMP Roundtable Discussion

BmDR Oversight Committee members Nicholas King, Katrina Peron, and Gary Friedman attended ASN Kidney Week 2024 in San Diego, California from October 23-27. They presented two posters detailed below. Members also attended the Kidney Precision Medicine Project (KPMP) Industry Roundtable on Wednesday, October 23, 2024.



Adjudication Methodology to Assess Novel Urine Biomarkers Panel Detection of Nephrotoxicant Exposure in Presence or Absence of KDIGO-Defined AKI to Support Biomarker Qualification
Presenter: Nicholas King



FAIR Access to Reusable Novel Biomarker Study Electronic Case Report Forms with Metadata Annotation and Statistical Analysis Plan Template for Biomarker Qualification
Presenter: Gary Friedman

PKDOC Annual Symposium Dinner

C-Path's Quantitative Medicine Scientific Director, Luke Kosinski, gives a presentation on the use of Disease Progression Models.

Features (from left to right) Nicholas King, Gary Friedman, and Katrina Peron at the PKDOC Annual Symposium dinner, where Gary gave a brief overview of BmDR.

How C-Path's Biomarker Data Repository Brings Patients to the Table to Discuss Biomarkers and their Impact

BmDR's work embodies C-Path's mission to lead collaborations that accelerate drug development and advance better treatments for people worldwide. C-Path generates solutions to facilitate scientific and regulatory pathways that accelerate the development of therapies for people with unmet medical needs. C-Path doesn't develop therapies; C-Path accelerates their development, helps them get to market faster, and helps improve patients' lives.

At a recent BmDR Community Engagement Committee meeting, Dave White detailed the frustrations patients face when treatments take too long to become available. "This takes me back to 2017 when I was with the Kidney Health Initiative, and we were in the midst of co-creating the Kidney Health Initiative's renal replacement therapy roadmap. One of the Patient Advisory Committee members became so frustrated that she quit because she couldn't understand why it took so long to be cured and have adequate treatments. We, as a team, didn't really know how to explain it either. That would have been the perfect time to explain the BmDR and what we are trying to develop."

To read more of this impact story, click here.

Biomarkers 101: A Patient's Perspective on the Importance of Identifying New Biomarkers

Kidney diseases are silent killers. For many patients, the detection of kidney problems through biomarkers marks the difference between a condition that can be managed versus a life-threatening disease. For instance, chronic kidney disease (CKD) often progresses silently without noticeable symptoms until it has advanced. Traditional biomarkers such as albumin in the urine or elevated serum creatinine levels allow for the early identification of CKD, giving patients and healthcare professionals the opportunity to implement lifestyle and treatment changes before the disease becomes more severe. For me, a routine employee physical found albumin in my urine when I was 20 years old. This early detection caused me to make diet and lifestyle changes that slowed the progression of my kidney disease. This biomarker data helped prevent the need for invasive treatments like dialysis or kidney transplantation for over 40 years.

To read more of Glenda's Blog Piece click here.

If you are interested in participating in the BmDR Oversight Committee or one of the sub-committees, please contact Nick King (nking@c-path.org) or Katrina Peron (kperon@c-path.org).

Recent Publications

Aubrecht, Jiri, David Potter, John Michael Sauer, Roscoe Warner, Kent Johnson, Mitchell R McGill, Katrina Peron, and Nicholas M P King. "Serum Glutamate Dehydrogenase Activity Enables Sensitive and Specific Diagnosis of Hepatocellular Injury in Humans." Toxicological Sciences, November 6, 2024. https://doi.org/10.1093/toxsci/kfae143.

Hartung, Thomas, Nicholas M. P. King, Nicole Kleinstreuer, Marcel Leist, and Danilo A. Tagle. "Leveraging Biomarkers and Translational Medicine for Preclinical Safety - Lessons for Advancing the Validation of Alternatives to Animal Testing." ALTEX - Alternatives to Animal Experimentation 41, no. 4 (October 22, 2024): 545–66. https://doi.org/10.14573/altex.2410011.

At a Glance

BmDR Website
BmDR DAP
C-Path DIKI Workshop - Patient Perspective Videos

If you have any questions about BmDR, please email bmdr@c-path.org.

Help support our mission. MAKE A GIFT TODAY

CRITICAL PATH INSTITUTE

1840 E River Rd, Suite 100 | Tucson, AZ 85718 | (520) 547-3440 | info@c-path.org
c-path.org

FDA Acknowledgment

This email was sent to [email address suppressed]. If you are no longer interested you can **unsubscribe instantly**.